| Title |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
|
|---|---|
| Published in |
Acta Medica Austriaca, January 2017
|
| DOI | 10.1007/s00508-016-1162-y |
| Pubmed ID | |
| Authors |
Sebastian Steiner, Theresa Bucsics, Philipp Schwabl, Mattias Mandorfer, Bernhard Scheiner, Maximilian Christopher Aichelburg, Katharina Grabmeier-Pfistershammer, Peter Ferenci, Michael Trauner, Markus Peck-Radosavljevic, Thomas Reiberger |
| Abstract |
We aimed to investigate the efficacy of interferon and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) and ritonavir boosted paritaprevir/ombitasvir with or without dasabuvir (2D/3D) regimens in a real-life cohort of human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfected patients. The study focused on efficacy, need for changes in antiretroviral therapy (ART) due to drug-drug interaction (DDI), and treatment-associated changes in liver stiffness. In this study 36 patients (n = 21 SOF/LDV and n = 15 2D/3D) were retrospectively analyzed. Depending on the genotype the following treatment regimens were used: HCV genotype (GT)-1: either SOF/LDV or 3D, no patient with HCV-GT2 was included, HCV-GT3: SOF/LDV, HCV-GT4: 2D. Approximately one third (35.3%) of patients were treatment-experienced and 13.9% had cirrhosis. Antiretroviral therapy had to be changed in 38.1% of SOF/LDV and 60% of 2D/3D patients prior to anti-HCV treatment due to expected DDIs. We observed sustained virologic response (SVR) rates of 100% in patients treated with SOF/LDV (19/19) and 2D/3D (14/14). One 2D/3D patient was lost to follow-up, while two SOF/LDV patients died during therapy from non-treatment-related causes. They were excluded from the analysis. Between baseline and follow-up liver stiffness decreased from 11.4 to 8.3 kPa (p = 0.008) and from 8.1 to 5.7 kPa (p = 0.001) in SOF/LDV and 2D/3D patients, respectively. We confirmed the excellent HCV eradication rates >95% in a real-life cohort of HIV/HCV coinfected patients treated with SOF/LDV and 2D/3D. We observed no HCV relapse or breakthrough. More patients treated with 2D/3D required a change in ART than patients treated with SOF/LDV. Additionally, HCV eradication led to a rapid decline in liver stiffness. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| Austria | 2 | 22% |
| Canada | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 22 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 3 | 14% |
| Student > Doctoral Student | 3 | 14% |
| Student > Bachelor | 3 | 14% |
| Student > Master | 2 | 9% |
| Librarian | 1 | 5% |
| Other | 2 | 9% |
| Unknown | 8 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 59% |
| Unknown | 9 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2019.
All research outputs
#7,200,862
of 25,377,790 outputs
Outputs from Acta Medica Austriaca
#233
of 967 outputs
Outputs of similar age
#125,222
of 422,653 outputs
Outputs of similar age from Acta Medica Austriaca
#4
of 12 outputs
Altmetric has tracked 25,377,790 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 967 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,653 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.